Altair Engineering's ROCE trend is concerning, having declined over the past five years. Despite this, the stock has yielded a 124% return to long-term shareholders, reflecting market optimism. However, if these trends continue, it may not be a multi-bagger in the future.
Altair Engineering's high P/S ratio may not be justified due to weak revenue forecasts. This could pose a risk to shareholders and potential investors as it may negatively impact the share price.
Altair Engineering's revenue growth, reflected in its rising share price, is the market's focus due to lack of profits. Recent positive sentiment suggests potential business momentum.
$アルテアエンジニアリング クラスA (ALTR.US)$low Reward/Risk ratio not interested here. hit hard several stonks panic buying not considering R/R ratio . No more emotions attached to fear of missing plays in market. always careful 👍🏻
The recent selling of shares by insiders at Altair Engineering, without any recorded purchases, may raise concerns among shareholders. Despite the high level of insider ownership, the lack of buying activity does not inspire confidence in the company's prospects.
Investors: monitor for potential price drop due to current overvaluation. Current timing may not be ideal for entry due to surpassing of true value. However, optimistic outlook suggests looking into other factors for next price drop.
Gainers: •$アクサム・セラピューティクス (AXSM.US)$+39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder) •$カプリコー・セラピューティクス (CAPR.US)$+4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
アルテアエンジニアリング クラスAに関するコメント
$アルテアエンジニアリング クラスA (ALTR.US)$
• $カーヴァナ (CVNA.US)$ : Raymond James Upgrades to Market Perform from Underperform
• $ニューモント (NEM.US)$ : Canaccord Upgrades to Buy from Hold - PT $66 (from $60)
• $ナイソース (NI.US)$ : Edward Jones Upgrades to Buy from Hold
• $シュルンベルジェ (SLB.US)$ : Benchmark Upgrades to Buy from Hold - PT $55
Downgrades
• $アジリシス (AGYS.US)$ : Craig-Hallum Downgrades to Hold from Buy
• $クリーブランド・クリフ (CLF.US)$ : GLJ Research Downgrades t...
• $アクサム・セラピューティクス (AXSM.US)$ +39.1% (received from FDA proposed labeling for the its AXS-05 product candidate with respect to its New Drug Application for AXS-05 for the treatment of major depressive disorder)
• $カプリコー・セラピューティクス (CAPR.US)$ +4% (announces statistically significant clinical benefits in skeletal muscle function in non-ambulant duchenne muscular dystrophy patients treated with CAP-1002 in HOPE-2 Open L...
まだコメントはありません